CDK4/6 inhibitors in advanced breast cancer, what is beyond?

  • Amrallah A. Mohammed | amrallaabdelmoneem@yahoo.com Medical Oncology Department, Faculty of Medicine, Zagazig University, Egypt; King Salman Armed Forces Hospital, Tabuk City, Saudi Arabia.
  • Hanaa Rashied El-mabra Hospital, Zagazig, Egypt.
  • Fifi Mostafa Elsayed Clinical Oncology & Nuclear Medicine, Department Faculty of Medicine Suez Canal University, Egypt.

Abstract

Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2019-07-29
Info
Issue
Section
Reviews
Keywords:
Breast cancer, CDK4/6 inhibitors, predictors of response and resistance.
Statistics
  • Abstract views: 988

  • PDF: 620
  • HTML: 15
How to Cite
Mohammed, A. A., Rashied, H., & Elsayed, F. M. (2019). CDK4/6 inhibitors in advanced breast cancer, what is beyond?. Oncology Reviews, 13(2). https://doi.org/10.4081/oncol.2019.416